Current adjuvant therapy with anti-PD-1 antibodies or targeted therapy in BRAF V600 mutant melanoma has improved 3-year RFS in high-risk stage III melanoma to 43–58% [3,4]. The gene discussed is BRAF; the disease is melanoma.